Skip to content

Effects of remazolam combined with propofol anesthesia on quality of recovery and hemodynamics after partial hepatic resection: a prospective randomized controlled trial

Effects of remazolam combined with propofol anesthesia on quality of recovery and hemodynamics after partial hepatic resection: a prospective randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086423
Enrollment
Unknown
Registered
2024-07-01
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Partial hepatectomy

Interventions

Remazolam combined with propofol group:Anesthesia induction: After full oxygenation and denitrification, patients were slowly injected with Sufentanil 0.3-0.4 µg/kg, remazolam 0.1mg /kg+ propofol 0.5-
RP group: intravenous pump remazolam 0.2-0.4 mg/(kg·h), propofol 1-4 mg/(kg·h)
At the end of the operation, patients in the RP group were given intravenous flumazenil 0.5 mg.
Propofol group:Anesthesia induction: After full oxygenation and denitrification, patients were slowly injected with Sufentanil 0.3-0.4 µg/kg, propofol 1-2.5 mg/kg (group P), and cisatracurium 0.15 mg/
Group P: intravenous pump propofol 2-8 mg/(kg·h)
At the end of the operation, patients in the P group were given intravenous saline of the same amount.

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Adult patients were selected for elective laparoscopic liver resection under general anesthesia, regardless of gender, age 18-80 years, BMI 18.5 ~ 28.0 kg/m^2, ASA II or III, and the expected time of surgery was 2 ~ 4 h

Exclusion criteria

Exclusion criteria: ? Complicated with severe kidney, heart and other organ dysfunction; ? Severe diseases of respiratory system, metabolic system and immune system; ? Coagulation function, neurological function, cognitive function impairment; ? History of allergic or adverse reactions to narcotic drugs used in this study; ?Unable to understand the written information or informed consent of the trial.

Design outcomes

Primary

MeasureTime frame
Time for patient to follow instructions (starting from the end of the procedure when the medication is stopped);

Secondary

MeasureTime frame
Time of CSI over 80 ;

Countries

China

Contacts

Public ContactFeng Yan

Affiliated Hospital of North Sichuan Medical College

1017018674@qq.com+86 158 8262 6422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026